High liver enzymes and celiac disease: how often, and what else is checked
Short answer
Raised ALT or AST turned up in 21.42% of people with celiac disease in one 2023 meta-analysis of 42 studies, and 86.39% of those with liver abnormalities responded to the gluten-free diet1, 2. When the numbers stay raised after about a year on the diet, reviews say other liver conditions need to be looked for, and a clinician decides how3, 4.
Part of Related conditions and complications, 16 guides

Key points
- In the five studies tabulated below, the share of people with celiac disease reported with raised liver enzymes ranged from 15.1% of children in one US study to 40.6% of adults in another5, 6.
- In the 2023 meta-analysis, celiac hepatitis was reported in nearly half of the people with celiac disease and liver involvement7.
- In a Boston study, most people with raised enzymes at diagnosis normalized them on the diet: 78.6% did, after a mean of 1.5±1.5 years8.
- Autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis can coexist with celiac disease and are non-responsive to the diet, according to a 2025 review9.
- Authors of two papers say enzymes that have not improved within a year on the diet call for considering another liver condition10, 4.
What do ALT and AST show?
ALT (alanine aminotransferase) and AST (aspartate aminotransferase) are liver enzymes that a blood test can measure11. The ACG guideline on abnormal liver chemistries defines hepatocellular injury as a disproportionate rise in AST and ALT compared with alkaline phosphatase12.
The same guideline says a true healthy normal ALT level ranges from 29 to 33 IU/l for males and 19 to 25 IU/l for females, and that levels above this should be assessed13.
In celiac disease, a 2018 review describes the rise as generally mild, with values greater than five times the upper limit of normal seen in a minority of patients14. The same review says celiac hepatitis is often asymptomatic15.
How often are liver enzymes raised in celiac disease?
The figures differ from study to study. The table gives each study’s own number and the group it looked at.
| Study | Who it looked at | What it reported |
|---|---|---|
| Meta-analysis (2011) | Adults with newly diagnosed celiac disease (the review found 11 eligible case series and case-control studies in all) | Pooled prevalence of abnormal serum transaminases 27% (95% CI 13% to 44%)16 |
| Database study, Boston (2015) | 463 adults with biopsy-proven celiac disease and an ALT or AST at diagnosis | 40.6% had elevated liver tests, against 24.2% of treated celiac patients and 16.6% of matched controls6 |
| Meta-analysis (2023) | 42 studies, 8976 patients, adults and children | Pooled proportion with elevated transaminases 21.42%; adults 21.20%, children 21.51%1 |
| Retrospective review, Ohio (2016) | 388 children; 185 had transaminases measured at diagnosis | 15.1% of those 185 had a raised ALT and/or AST5 |
| Prospective study, Tel Aviv (2022) | 125 newly diagnosed children | 24.8% had a raised ALT (the study set its ALT threshold at 24 U/l); 1.6% were over 3 times the upper limit of normal17 |
In both pediatric series the children with raised enzymes were younger than those without18, 19.
Some people without celiac disease have raised liver tests too: in the Boston study, 16.6% of matched controls did6.
What is celiac hepatitis?
A 2025 review defines “celiac hepatitis” as abnormal liver function tests and/or histological changes on liver biopsy, in the absence of other causes, which resolves with a gluten-free diet20.
That definition depends on what happens after the diet starts. A 2018 review says that if raised transaminases return to normal after gluten is excluded, a diagnosis of celiac hepatitis is confirmed21.
Among people with celiac disease and liver involvement, the 2023 meta-analysis reports celiac hepatitis in nearly half7.
How often, and how fast, do liver enzymes return to normal on the diet?
| Study | What it reported |
|---|---|
| Meta-analysis (2011) | Exclusion of gluten led to normalisation of serum transaminase levels in 63% to 90% of patients within 1 year16 |
| Database study, Boston (2015) | 78.6% of those with elevated liver tests at diagnosis normalized them on the diet after a mean of 1.5±1.5 years8 |
| Meta-analysis (2023) | 86.39% of people with liver abnormalities showed a response to the diet2 |
| Retrospective review, Ohio (2016), children | Of 21 with raised transaminases and repeat tests, 15 (71.4%) normalized and 6 (28.6%) stayed raised22 |
| Prospective study, Tel Aviv (2022), children | 80% of children with a raised ALT normalized within 3 months, and all within 1 year23 |
A 2018 review says that in the majority of patients the diet brings previously raised transaminases back to normal within 1 year, and that only a small percentage need longer24, 25.
Two reviews describe when the first re-check falls. The 2025 review says liver enzymes should be repeated 6 to 12 months after a strict diet starts26. The 2018 review recommends a “treat-first then re-evaluate” approach, rather than initial extensive investigations, for asymptomatic raised transaminases below five times the upper limit of normal, with an AST/ALT ratio below 1 and normal physical and ultrasound examinations27. These are the reviews’ statements about clinical practice, not advice for any one person.
If they stay raised: what else a clinician looks for
Several papers say the same thing. The Boston study concluded that a coexisting liver disorder should be considered in patients whose liver tests have not improved within a year on the diet10. The 2018 review says that lack of normalization within a year despite adherence to the diet increases the probability of another concomitant liver disease, of autoimmune, viral, metabolic or toxic origin, and that a thorough hepatologic examination is then necessary4. The pediatric Tel Aviv study says significant elevations that fail to normalize on the diet warrant further investigation28.
Abnormal liver tests during follow-up of someone who is strictly adhering to the diet should also raise suspicion of other liver disease, the 2018 review adds29.
The ACG guideline lists what its evaluation of a hepatocellular pattern includes: testing for viral hepatitis A, B and C, assessment for nonalcoholic fatty liver disease and alcoholic liver disease, and screening for hereditary hemochromatosis, autoimmune hepatitis, Wilson’s disease and alpha-1 antitrypsin deficiency. It adds that a history of prescribed and over-the-counter medicines should be sought30. When alkaline phosphatase is raised and of liver origin, it says testing for primary biliary cholangitis and primary sclerosing cholangitis should be undertaken31.
| Condition | What NIDDK says it is | How testing relates to it |
|---|---|---|
| Nonalcoholic fatty liver disease | A condition in which fat builds up in the liver32 | NIDDK says a doctor may suspect it if a blood test shows increased ALT and AST33 |
| Autoimmune hepatitis | A chronic disease in which the immune system attacks the liver, causing inflammation and damage34 | NIDDK says ALT and AST are particularly important because they are highly elevated in people with it35 |
| Primary biliary cholangitis | A chronic disease in which the small bile ducts in the liver become injured and inflamed and are eventually destroyed36 | NIDDK says higher-than-normal alkaline phosphatase occurs in diseases that destroy or block the bile ducts, such as this one37 |
| Viral hepatitis | An infection that causes liver inflammation and damage38 | Hepatitis A, B and C testing is on the ACG list above30 |
The 2025 review adds that autoimmune hepatitis, primary biliary cholangitis and primary sclerosing cholangitis can coexist with celiac disease and are non-responsive to the gluten-free diet9. It names drug or toxin-related injury alongside the others in its list of what to exclude when transaminases remain elevated after a year on the diet3.
Findings that, in one review, call for a wider search at diagnosis
The 2018 review says people whose liver tests are raised when celiac disease is diagnosed need an extended search for other liver disease when the picture does not fit celiac hepatitis39. It lists these features:
- transaminases above five times the upper limit of normal, or an AST/ALT ratio above 1;
- laboratory signs of cholestasis (raised gamma glutamyl transferase, liver-origin alkaline phosphatase or bilirubin);
- a liver disorder that causes symptoms;
- physical or ultrasound signs that suggest a liver disorder.
This is one review’s wording of when to look further. It is not a way to rule a cause in or out from home.
Fatty liver and celiac disease
NIDDK says nonalcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in the liver32, and that it is usually a silent disease with few or no symptoms40. The 2025 review notes that NAFLD is now included in the category of metabolic dysfunction-associated steatotic liver disease (MASLD)41.
A 2024 meta-analysis of 11 studies (n = 2578)42 reported fatty liver in 18.2% (95% CI 8.3-30.8%) of people with celiac disease who had not yet started the diet, and in 28.2% (95% CI 20.7-36.4%) of those on the diet for varying lengths of time. Its figures for metabolic syndrome were 4.3% and 21.3%43.
The two reviews name different contributors. The 2018 review says fatty liver in people with celiac disease may occur as a metabolic sequel of malabsorption and long-standing malnutrition44, and that the diet usually leads to resolution of steatosis in these people45. The 2025 review says age, sex and body mass index could contribute to persistent elevation of liver enzymes46, and that a diet built on gluten-free counterparts rich in sugars and fat can promote metabolic alterations such as hepatic steatosis47.
If the liver result came first
The question also runs the other way. In a 2011 meta-analysis, the pooled prevalence of positive celiac serology among adults with cryptogenic hypertransaminasemia was 6%, and of biopsy-proven celiac disease 4%48. A 2023 meta-analysis put biopsy-confirmed celiac disease in cryptogenic hypertransaminasemia at 5.7% (3.2%-8.8%)49, and its authors wrote that nearly 1 in 20 patients with cryptogenic hypertransaminasemia have celiac disease and that this group should be considered high-risk for it50.
The 2018 review recommends integrating celiac disease screening into the work-up of unexplained hypertransaminasemia, among other liver presentations51.
The Boston authors note that guidelines recommend routine screening of liver function tests in patients diagnosed with celiac disease52.
Questions to bring to the clinic
These are prompts we wrote for a conversation with a gastroenterologist or hepatologist. They are not taken from any guideline.
- Which liver tests were measured (ALT, AST, alkaline phosphatase, bilirubin), and how far was each from the lab’s range?
- Were they drawn before or after the gluten-free diet started, and when will they be repeated?
- Which other causes does the clinician think are worth checking in my case, and why those?
- Could a medicine or supplement I take be part of the picture? (Bring the whole list, including over-the-counter products.)
- Have my celiac antibody tests been repeated, and what did they show?
- Who follows this up: my gastroenterologist, a hepatologist, or my primary care clinician?
Questions people ask
Can celiac disease cause high ALT and AST?
It is reported. In a 2023 meta-analysis of 42 studies, the pooled proportion of people with celiac disease and elevated transaminases was 21.42%1.
Do liver enzymes go back to normal on a gluten-free diet?
In the studies reported, most did. In the 2023 meta-analysis 86.39% of those with liver abnormalities showed a response to the diet2, and an earlier meta-analysis reported normalisation of transaminases in 63% to 90% of patients within 1 year16.
How long does it take?
It varies by study. The Boston study reported a mean of 1.5±1.5 years8; in the Tel Aviv pediatric study all children had normalized within 1 year23. A 2018 review says a small percentage need longer25.
What if liver enzymes stay high on the diet?
Two papers say that enzymes not improving within a year on the diet call for considering another liver condition10, 4; one adds that this raises its probability and that a thorough hepatologic examination is then necessary4.
How common is fatty liver in celiac disease?
A 2024 meta-analysis reported fatty liver in 18.2% of people with celiac disease before the diet and 28.2% of those on it for varying lengths of time43.
More in Related conditions and complications
Celiac disease and other autoimmune conditions: which pairings have testing adviceWhich autoimmune conditions are reported with celiac disease, which have testing advice from named bodies, and which do not.
SIBO and celiac disease: how often it is found and what testing showsWhat studies report about SIBO in celiac disease, how breath tests work and where they fall short, and and what else is checked when symptoms persist.
Celiac disease and thyroid disease: how they are linked and which tests the guidelines nameHow often celiac and thyroid disease occur together, which tests guidelines name in each direction, and how to check a thyroid tablet’s label.
Eosinophilic esophagitis and celiac disease: how they differ and how each is diagnosedHow eosinophilic esophagitis and celiac disease differ, what studies report about having both, how each is diagnosed, and how their diets differ.
Celiac disease and tooth enamel defects: what they are, who gets them, what a dentist can doWhat studies say about celiac disease and enamel defects: when they form, how common they are, what dentists can do, and toothpaste gluten statements.
Celiac disease, vaccines and the spleen: what the guidance saysWhat published guidance says on hepatitis B vaccine response, reduced spleen function and pneumococcal vaccination in celiac disease.
Related guides
Follow-up testing after a celiac diagnosis: what the guidelines listWhat celiac guidelines and charities list for follow-up: antibody checks, repeat biopsy, nutrient tests, and what is checked if symptoms continue.
Celiac disease complications and cancer risk: how to read the numbersWhat NIDDK, Coeliac UK, a 2025 European guideline and Swedish cohort studies report on celiac disease complications and cancer, relative next to absolute.
Gluten in medications: what the label, DailyMed and a pharmacist can showFDA’s gluten-free food rule does not cover drugs. Use the ingredient list, DailyMed, the maker and a pharmacist, and know what each can show.
Celiac Blood Tests: What tTG-IgA, Total IgA, DGP and EMA Each CheckWhat tTG-IgA, total IgA, EMA and DGP check, why total IgA is drawn with tTG-IgA, when back-up tests are used, and why gluten stays in the diet first.
Sources
- [1, 2, 7] Journal of Gastroenterology and Hepatology, Liver abnormalities in celiac disease and response to gluten free diet: a systematic review and meta-analysis (Jena 2023, abstract), checked Nov 17, 2026.
- [3, 9, 20, 26, 41, 46, 47] Liver International, Liver Involvement in Celiac Disease and Immune-Mediated Diseases of the Small Bowel (2025 review), checked Nov 17, 2026.
- [4, 14, 15, 21, 24, 25, 27, 29, 39, 44, 45, 51] Nutrients, Celiac Disease and Liver Disorders: From Putative Pathogenesis to Clinical Implications (Hoffmanová 2018 review), checked Nov 17, 2026.
- [5, 18, 22] Journal of Pediatric Gastroenterology and Nutrition, Hypertransaminasemia in newly diagnosed pediatric patients with celiac disease (Lee 2016, abstract), checked Nov 17, 2026.
- [6, 8, 10, 52] American Journal of Gastroenterology, Prevalence of abnormal liver function tests in celiac disease and the effect of a gluten-free diet in the US population (Castillo 2015, abstract), checked Nov 17, 2026.
- [11, 35] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Autoimmune Hepatitis: Diagnosis, checked Nov 17, 2026.
- [12, 13, 30, 31] American College of Gastroenterology (American Journal of Gastroenterology), ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries (abstract), checked Nov 17, 2026.
- [16, 48] Alimentary Pharmacology & Therapeutics, Meta-analysis: Coeliac disease and hypertransaminasaemia (Sainsbury 2011, abstract), checked Nov 17, 2026.
- [17, 19, 23, 28] European Journal of Pediatrics, Elevated liver enzymes of newly diagnosed pediatric celiac patients: a prospective-observational study (Regev 2022, abstract), checked Nov 17, 2026.
- [32, 40] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Nonalcoholic Fatty Liver Disease (NAFLD) & NASH, checked Nov 17, 2026.
- [33] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Nonalcoholic Fatty Liver Disease (NAFLD) & NASH: Diagnosis, checked Nov 17, 2026.
- [34] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Autoimmune Hepatitis, checked Nov 17, 2026.
- [36] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Primary Biliary Cholangitis, checked Nov 17, 2026.
- [37] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Primary Biliary Cholangitis: Diagnosis, checked Nov 17, 2026.
- [38] National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Viral Hepatitis, checked Nov 17, 2026.
- [42, 43] Digestive Diseases and Sciences, Patients with celiac disease have high prevalence of fatty liver and metabolic syndrome (Aggarwal 2024, abstract), checked Nov 17, 2026.
- [49, 50] American Journal of Gastroenterology, Prevalence of celiac disease in patients with liver diseases: a systematic review and meta-analyses (Yoosuf 2023, abstract), checked Nov 17, 2026.